Grace Therapeutics (GRCE) 10% Owner Opaleye Management Buys Shares

What Happened

• Opaleye Management, Inc. (identified as a 10% owner via its role as investment manager to Opaleye, L.P.) made two open-market purchases of Grace Therapeutics (GRCE) common stock. On 2026-09-08 it acquired 9,393 shares at a weighted average price of $2.10 (total $19,699). On 2026-09-09 it acquired 5,836 shares at a weighted average price of $2.09 (total $12,197). Combined purchases: 15,229 shares for $31,896. These were purchases (not sales), which are generally considered more informative to investors than routine sell transactions.

Key Details

• Transaction dates and prices:
  • 2026-09-08: 9,393 shares @ weighted avg $2.10 (range $2.095–$2.10) — $19,699 (F2)
  • 2026-09-09: 5,836 shares @ weighted avg $2.09 (range $2.085–$2.09) — $12,197 (F3)
• Total: 15,229 shares purchased for $31,896.
• Shares owned after transaction: Not specified in the excerpt provided.
• Footnotes of note:
  • F1: Shares are owned directly by Opaleye, L.P.; Opaleye Management, Inc. is the fund’s investment manager and may be deemed to beneficially own those shares.
  • F2/F3: Reported prices are weighted averages across multiple trades; the filer will provide per-trade details on request.
  • F4: Opaleye Management disclaims beneficial ownership except to the extent of its pecuniary interest.
• Timeliness: Form 4 was filed 2026-09-10 covering trades on 2026-09-08 and 2026-09-09; the filing appears timely.

Context

• This filing reflects institutional fund buying (Opaleye as manager of Opaleye, L.P.), not an individual executive’s personal trade. Institutional purchases can signal portfolio allocation decisions but are not the same as insider executive voting or operational confidence. The filing includes standard weighted-average pricing disclosures and a disclaimer about beneficial ownership.